Biomedtracker

Report Library

2015 Post-ADA Report - Part II, Supplement

July 28, 2015

Part II of our 2015 Post-ADA Report provides:

Highlights from a pulse survey we conducted among primary care physicians on the FDA warning about diabetic ketoacidosis (DKA) with SGLT2 Inhibitors in Type 2 diabetics. For opinions from endocrinologists, please see Part I of the 2015 Post-ADA Report. For the full survey, please see this link.
An analysis of all the industry-sponsored trials presented at the 2015 ADA conference from Citeline’s Trialtrove®. This includes number of abstracts, clinical phases, diseases covered, top drugs, and locations of trials.

For coverage of the data presented at the conference--along with an overview of the ongoing and planned clinical trials in Type 2 diabetes and diabetes pipeline from Citeline’s Trialtrove® and Pharmaprojects®--please see the previously published Part I of the report.

Indications Covered:

Complement Deficiencies / Abnormalities

Additional Resources: